Paxerol (a Novel Formulation of Acetaminophen and Ibuprofen) for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

Trial Profile

Paxerol (a Novel Formulation of Acetaminophen and Ibuprofen) for Treatment of Nocturia - A Phase II Placebo-Controlled Trial

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Nov 2016

At a glance

  • Drugs Ibuprofen/paracetamol (Primary)
  • Indications Nocturia
  • Focus Therapeutic Use
  • Sponsors Wellesley Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2016 Planned End Date changed from 1 Jul 2016 to 1 Mar 2017.
    • 01 Nov 2016 Planned primary completion date changed from 1 Jun 2016 to 1 Feb 2017.
    • 04 Apr 2016 Planned number of patients changed from 40 to 100 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top